Abbott Laboratories (ABT) Earnings: Q3 2026 Results and Next Report Date

The quarter ended September 30, 2026 and Abbott published the results on October 21, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Abbott reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Abbott completed its acquisition of Exact Sciences on March 23, 2026; its sales are reported as Cancer Diagnostics inside Diagnostics. Reported growth includes that business, while Abbott's comparable sales growth (7.0% in Q3 2026) adds Exact Sciences' sales to the prior year and excludes foreign exchange.
• Segment year-ago figures are from Note 15 of Abbott's 10-Q. From January 1, 2026, the Amulet occluder moved from Structural Heart to Electrophysiology, shifting $55 million of Q3 2025 sales.

Source: Abbott Q3 2026 results (Form 8-K, Exhibit 99.1), October 21, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Abbott splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Abbott's Nutrition revenue was $2.3 billion in Q3 2026, up 5% from $2.2 billion in Q3 2025, 17% of total revenue.
• Abbott's Diagnostics revenue was $3.3 billion in Q3 2026, up 47% from $2.3 billion in Q3 2025, 25% of total revenue.
• Abbott's Established Pharmaceuticals revenue was $1.6 billion in Q3 2026, up 7% from $1.5 billion in Q3 2025, 12% of total revenue.
• Abbott's Medical Devices revenue was $5.8 billion in Q3 2026, up 7% from $5.4 billion in Q3 2025, 45% of total revenue.
• Abbott's Other revenue was $6.0 million in Q3 2026, up 50% from $4.0 million in Q3 2025, under 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Abbott said:

“Abbott projects full-year 2026 adjusted diluted earnings per share of $5.50 to $5.55.”

“Abbott projects fourth-quarter 2026 adjusted diluted earnings per share of $1.62 to $1.67.”

“Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted diluted EPS guidance range and tightens the range to $5.50 to $5.55.”

Source: Abbott Q3 2026 release, Oct 21, 2026.

This is the company's own guidance as of Oct 21, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the ABT forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net sales and diluted EPS, each as first reported in that quarter's release. Quarters from Q2 2026 include Exact Sciences, acquired March 23, 2026.

Abbott's next report is expected around January 28, 2027, a date estimated from its reporting history that the company has not yet confirmed. This page will show Q3 2026 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 21, 2026

Abbott reports four businesses. In Q3 2026 Medical Devices was the largest at $5,826 million of $13,013 million in net sales, followed by Diagnostics at $3,305 million, Nutrition at $2,262 million and Established Pharmaceuticals at $1,614 million. Reported sales rose 14.5%, and 7.0% on Abbott's comparable basis. (Abbott Q3 2026 release, Oct 21, 2026)

Most of the reported increase came from the Exact Sciences acquisition, which Abbott completed on March 23, 2026 for approximately $20.6 billion, funded primarily through $20.0 billion of new long-term debt. Its sales now appear as Cancer Diagnostics, $968 million in the quarter, which lifted U.S. Diagnostics sales 109.2%. On a comparable basis Cancer Diagnostics grew 13.8%, driven by Cologuard. (Abbott Q3 2026 release, Oct 21, 2026; Abbott Form 10-Q, Q3 2026, Nov 4, 2026)

Within Medical Devices, Diabetes Care was $2,185 million, and sales of continuous glucose monitors grew 7.3% on a reported basis. Electrophysiology rose 15.0% to $873 million and Rhythm Management 9.7% to $752 million. For the first nine months, Abbott's CGM systems sales totaled $6.2 billion, against $5.6 billion a year earlier. (Abbott Q3 2026 release, Oct 21, 2026; Abbott Form 10-Q, Q3 2026, Nov 4, 2026)

Established Pharmaceuticals sells branded generics only outside the U.S.; its Key Emerging Markets sales rose 9.0% to $1,195 million, led by India and markets in Latin America and Asia Pacific. Nutrition rose 5.1%, with Pediatric up 8.8%. International sales were $7,509 million of the total and U.S. sales $5,504 million. (Abbott Q3 2026 release, Oct 21, 2026)

Abbott's GAAP diluted EPS fell to $0.53 in Q3 2026 while adjusted EPS rose to $1.42. Specified items of $0.89 per share separate them: intangible amortization of $841 million, legal settlements of approximately $670 million and $178 million of other net expenses tied to acquisitions and restructuring. Amortization doubled from $420 million a year earlier with the Exact Sciences intangibles, including approximately $100 million from measurement period adjustments in the quarter. (Abbott Q3 2026 release, Oct 21, 2026; Abbott Form 10-Q, Q3 2026, Nov 4, 2026)

The legal charge is Abbott's preterm infant formula litigation: in Q3 2026 it recorded approximately $670 million for agreements to resolve the Gill case, a $495 million state court verdict, and NEC claims brought on behalf of approximately 2,000 additional infants. Separately, in September 2026 Abbott paid approximately $385 million to resolve DOJ investigations and a qui tam lawsuit over its U.S. powdered infant formula manufacturing. Interest expense rose to $350 million from $121 million after the acquisition debt. (Abbott Form 10-Q, Q3 2026, Nov 4, 2026)

The GAAP tax rate was 25.3%, against 15.2% excluding specified items. Diluted shares averaged 1,738 million, against 1,749 million a year earlier; Abbott repurchased approximately 11.6 million shares for $1.0 billion in the first nine months of 2026, with $5.6 billion remaining under its authorization. (Abbott Q3 2026 release, Oct 21, 2026; Abbott Form 10-Q, Q3 2026, Nov 4, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Abbott gives adjusted EPS guidance and a comparable sales growth figure in its release, with no GAAP equivalent. With Q3 2026 results it tightened full-year 2026 adjusted diluted EPS guidance to $5.50 to $5.55, keeping the midpoint, guided fourth-quarter adjusted EPS of $1.62 to $1.67, and projected full-year comparable sales growth of approximately 6.0%. (Abbott Q3 2026 release, Oct 21, 2026)

A consensus figure is the average of the models published by the analysts who cover Abbott, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Abbott's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning ABT is on is ABT a buy or a sell?, what analysts expect next is on the ABT forecast, and what the company does is on the Abbott Laboratories (ABT) stock page.

Every number on this page can be traced to a document Abbott published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.